Dr Florez on the Significance of the First Latin American Workshop in EGFR+ Lung Cancer

“This first Latin America workshop is the beginning of how more inclusive practices will allow physicians from Latin America to learn from experts in the field [about EGFR-mutant lung cancer], which is the most common lung cancer mutation in Latin America, ranging from 30% in Brazil to up to 50% of the lung cancers in Peru.”

Narjust Florez, MD, associate medical director of the Cancer Care Access Program and a thoracic medical oncologist at Dana-Farber Cancer Institute, discussed a trilingual, multidisciplinary workshop that was held at the 2026 ASCO Annual Meeting, which addressed the continuum of EGFR-mutated non–small cell lung cancer (NSCLC) for oncologists practicing in Latin America.

The workshop, which was conducted in English, Portuguese, and Spanish was designed to reach oncologists across Latin America managing patients with EGFR-mutant NSCLC. The session was co-led by a surgeon, a medical oncologist, and a radiation oncologist, each with direct experience treating patients in the region, and was designed around real patient cases rather than didactic review of trial data alone, Florez explained.

Discussion spanned the disease continuum from resectable to metastatic disease. In the early-stage setting, participants worked through a case of stage II, node-positive NSCLC to evaluate neoadjuvant chemotherapy plus osimertinib (Tagrisso), referencing data from the phase 3 NeoADAURA trial (NCT04351555), followed by discussion of adjuvant osimertinib after surgery. A second case addressed unresectable, EGFR-mutant NSCLC managed with chemoradiotherapy, incorporating findings from the phase 3 LAURA trial (NCT03521154) on consolidation osimertinib following chemoradiation. Participants were presented with evolving complications to each case and contributed perspectives reflecting practice realities across multiple Latin American countries, Florez stated.

The metastatic setting covered intensification regimens including osimertinib plus chemotherapy as investigated in the phase 3 FLAURA2 trial (NCT04035486) and amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) from the phase 3 MARIPOSA trial (NCT04487080), both now considered standard first-line options in EGFR-mutant metastatic NSCLC. The workshop closed with discussion of local consolidative therapy for oligometastatic disease, including which patients may be candidates for surgery or radiation following response to systemic therapy.

Florez concluded by noting that EGFR mutations account for an estimated 30% to 50% of NSCLC cases across Latin American countries, including Brazil and Peru, respectively. As such, the workshop is intended as the first in an ongoing series aimed at improving access to region-relevant, expert-led education for Latin American oncologists.